keyword
MENU ▼
Read by QxMD icon Read
search

schizophrenia and smoking cessation

keyword
https://www.readbyqxmd.com/read/29575323/clozapine-reduces-nicotine-self-administration-blunts-reinstatement-of-nicotine-seeking-but-increases-responding-for-food
#1
Andrew R Abela, Zhaoxia Li, Anh D Lê, Paul J Fletcher
People with schizophrenia display significantly higher rates of smoking than the general population, which may be due to an interaction between nicotine and antipsychotic medication. While the conventional antipsychotic drug haloperidol sometimes increases cigarette smoking in patients with schizophrenia, there is some evidence suggesting that clozapine, an atypical antipsychotic drug, may reduce nicotine use in these patients. However, the effects of antipsychotic drugs like clozapine on aspects of nicotine self-administration and reinstatement have not been systematically examined...
March 25, 2018: Addiction Biology
https://www.readbyqxmd.com/read/29563871/naltrexone-and-bupropion-combination-treatment-for-smoking-cessation-and-weight-loss-in-patients-with-schizophrenia
#2
Xuechan Lyu, Jiang Du, Guilai Zhan, Yujie Wu, Hang Su, Youwei Zhu, Fredrik Jarskog, Min Zhao, Xiaoduo Fan
Objective: The rates of obesity and cigarette smoking are much higher in patients with schizophrenia compared to the general population. This study was to examine whether naltrexone and bupropion combination treatment can help weight loss and smoking cessation in patients with schizophrenia. Methods: Obese male schizophrenia patients with current cigarette smoking were randomized to receive adjunctive naltrexone (25 mg/day) and bupropion (300 mg/day) combination or placebo for 24 weeks. Twenty-two patients were enrolled in the study, and 21 patients completed the study (11 in the treatment group, and 10 in the placebo group)...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29486960/effects-of-short-term-high-frequency-repetitive-transcranial-magnetic-stimulation-to-bilateral-dorsolateral-prefrontal-cortex-on-smoking-behavior-and-cognition-in-patients-with-schizophrenia-and-non-psychiatric-controls
#3
Karolina Kozak, Maryam Sharif-Razi, Marya Morozova, Erin V Gaudette, Mera S Barr, Zafiris J Daskalakis, Daniel M Blumberger, Tony P George
BACKGROUND: High rates of tobacco smoking and smoking cessation failure in schizophrenia may be related to prefrontal cortical dysfunction. Novel treatment options for tobacco use disorder are needed given the limited efficacy of current pharmacotherapies. Preliminary evidence suggests high-frequency repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsolateral prefrontal cortex (DLPFC) may suppress tobacco craving in smokers with schizophrenia. The goal of this study was to determine effects of rTMS for tobacco craving and cognition using a short-term (3-day) human laboratory paradigm...
February 24, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29459327/changes-in-tobacco-consumption-in-cannabis-dependent-patients-with-schizophrenia-versus-non-psychiatric-controls-during-28-days-of-cannabis-abstinence
#4
Rachel A Rabin, Sarah S Dermody, Tony P George
BACKGROUND: Tobacco and cannabis are highly co-morbid in the general population and in patients with schizophrenia. Given the putative causal mechanisms facilitating co-use, it is important to determine how cannabis cessation may influence concurrent tobacco use. Using a 28-day cannabis abstinence paradigm, we prospectively examined changes in tobacco consumption in patients with schizophrenia and controls with cannabis dependence and daily cigarette use. METHODS: Cannabis dependent patients with schizophrenia (n = 19) and controls (n = 20) completed the study with abstinence rates of 42% and 55%, respectively...
April 1, 2018: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/29396753/tobacco-smoking-is-associated-with-antipsychotic-medication-physical-aggressiveness-and-alcohol-use-disorder-in-schizophrenia-results-from-the-face-sz-national-cohort
#5
J Mallet, Y Le Strat, F Schürhoff, N Mazer, C Portalier, M Andrianarisoa, B Aouizerate, F Berna, L Brunel, D Capdevielle, I Chereau, T D'Amato, J Dubreucq, C Faget, F Gabayet, R M Honciuc, C Lançon, P M Llorca, D Misdrahi, R Rey, P Roux, A Schandrin, M Urbach, P Vidailhet, G Fond, C Dubertret
Tobacco smoking is common in schizophrenia and is one of the main causes of premature mortality in this disorder. Little is known about clinical correlates and treatments associated with tobacco smoking in patients with schizophrenia. Still, a better characterization of these patients is necessary, in a personalized care approach. Aggressiveness and childhood trauma have been associated with tobacco smoking in general population, but this association has never been explored in schizophrenia. Our study examines the clinical and therapeutic characteristics of tobacco smoking in schizophrenia...
February 2, 2018: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/29301614/metabotropic-glutamate-receptors-2-and-3-as-targets-for-treating-nicotine-addiction
#6
REVIEW
Alan J Cross, Robert Anthenelli, Xia Li
Tobacco smoking, driven by the addictive properties of nicotine, continues to be a worldwide health problem. Based on the well-established role of glutamatergic neurotransmission in drug addiction, novel medication development strategies seek to halt nicotine consumption and prevent relapse to tobacco smoking by modulating glutamate transmission. The presynaptic inhibitory metabotropic glutamate receptors 2 and 3 (mGluR2/3) are key autoreceptors on glutamatergic terminals that maintain glutamate homeostasis...
November 21, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/29185480/initial-cross-over-test-of-a-positive-allosteric-modulator-of-alpha-7-nicotinic-receptors-to-aid-cessation-in-smokers-with-or-without-schizophrenia
#7
Kenneth A Perkins, K N Roy Chengappa, Joshua L Karelitz, Margaret C Boldry, Valerie Michael, Taylor Herb, Jessica Gannon, Jaspreet Brar, Lisa Ford, Stefanie Rassnick, Darlene H Brunzell
Preclinical research shows that compounds acting at α7 nicotinic receptors (nAChRs) can reduce nicotine self-administration, suggesting that a positive allosteric modulator (PAM) of α7 receptors, JNJ-39393406, may aid smoking cessation. Moreover, individuals with schizophrenia, who have very high rates of smoking, have reduced expression of α7 nAChRs and may particularly benefit from this compound. In two parallel studies using a within-subject cross-over design, 36 healthy smokers (Study 1) and 62 smokers with schizophrenia (Study 2), both groups high in quit interest, attempted to initiate quitting temporarily during each of two 3-week phases...
November 29, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29164928/clozapine-diabetes-mellitus-cardiovascular-risk-and-mortality-results-of-a-21-year-naturalistic-study-in-patients-with-schizophrenia-and-schizoaffective-disorder
#8
Katlyn L Nemani, M Claire Greene, Melissa Ulloa, Brenda Vincenzi, Paul M Copeland, Sulaiman Al-Khadari, David C Henderson
The goal of this 21-year naturalistic study of clozapine treated patients was to examine the cardiovascular risk factors following clozapine initiation and resultant mortality estimates from cardiovascular disease. Data was collected from medical records of clozapine treated patients with schizophrenia or schizoaffective disorder from January 1992 to February 2012. Demographics, clozapine dosage and laboratory results were extracted at 12-month intervals. At clozapine initiation, the mean age of 96 patients was 36...
November 22, 2017: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/29137560/randomized-trial-of-interventions-for-smoking-cessation-among-medicaid-beneficiaries-with-mental-illness
#9
Mary F Brunette, Sarah I Pratt, Stephen J Bartels, Emily A Scherer, Stacey C Sigmon, Joelle C Ferron, Meghan Santos, Gail E Williams, Samuel Kosydar, Rosemarie S Wolfe, Doris Lotz, Kelley Capuchino
OBJECTIVE: Medicaid beneficiaries with severe mental illnesses are a financially disadvantaged group with high rates of smoking and poor cessation outcomes. This study examined whether abstinence-contingent monetary incentives improved outcomes when added to cessation treatments at community mental health centers: prescriber visit for pharmacotherapy only (PV only), prescriber visit and facilitated quitline (PV+Q), and prescriber visit and telephone cognitive-behavioral therapy (PV+CBT)...
March 1, 2018: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/29106683/neural-responses-to-smoking-cues-in-schizophrenia
#10
Lauren V Moran, Jennifer M Betts, Dost Ongur, Amy C Janes
The high prevalence of nicotine dependence contributes to excess mortality in schizophrenia. Cue reactivity, or the encounter of drug-related cues or contexts, triggers craving, drug-seeking, and relapse. Prior functional magnetic resonance imaging (fMRI) research indicates that individuals with schizophrenia have blunted neural responses to rewarding stimuli in association with more severe negative symptoms. The objectives of this study are to determine if smokers with schizophrenia have altered neural reactivity to smoking cues compared with non-psychiatrically ill smokers and to evaluate the influence of negative symptoms on cue reactivity...
July 4, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29065847/long-term-administration-of-antipsychotic-drugs-in-schizophrenia-and-influence-of-substance-and-drug-abuse-on-the-disease-outcome
#11
F-M Werner, Rafael Coveñas
BACKGROUND: Many schizophrenic patients with a long-term administration of antipsychotic drugs do not regularly adhere to the prescribed pharmacotherapy. Antipsychotic drugs constitute a palliative, but not a curative treatment, and the long-term effect of these drugs is not secure. Patients tend to consume nicotine and alcohol, as well as some patients consume drugs such as cannabis and amphetamines. OBJECTIVE: The objective of this mini-review is to examine the reasons for the high tendency of schizophrenic patients to consume alcohol, nicotine and drugs and in addition to suggest measures to reduce the abuse of substances and drugs...
October 20, 2017: Current Drug Abuse Reviews
https://www.readbyqxmd.com/read/29059417/brief-web-based-interventions-for-young-adult-smokers-with-severe-mental-illnesses-a-randomized-controlled-pilot-study
#12
Mary F Brunette, Joelle C Ferron, Delbert Robinson, Daniel Coletti, Pamela Geiger, Timothy Devitt, Vanessa Klodnick, Jennifer Gottlieb, Haiyi Xie, Mary Ann Greene, Douglas Ziedonis, Robert E Drake, Gregory J McHugo
Significance: About 50% of young adults with schizophrenia, bipolar disorder, and other severe mental illnesses smoke tobacco, but few studies have evaluated interventions for this group. Methods: We conducted a randomized pilot study among 58 young adult smokers with severe mental illnesses comparing a brief interactive web-based motivational tool, Let's Talk About Smoking, to computerized standard education from the National Cancer Institute. An additional 23 subjects received minimal tobacco assessment at baseline and no intervention, providing a comparison condition for naturalistic cessation behavior...
October 14, 2017: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/28841509/exploring-online-communication-about-cigarette-smoking-among-twitter-users-who-self-identify-as-having-schizophrenia
#13
Yulin Hswen, John A Naslund, Pooja Chandrashekar, Robert Siegel, John S Brownstein, Jared B Hawkins
Novel approaches are needed to address elevated tobacco use among people with schizophrenia. This exploratory study examined the frequency, timing, and type of communication about tobacco-related content on Twitter among users who self-identify as having schizophrenia compared with users from the general population. Over a 200-day period from January to July 2016, Twitter users who self-identify as having a schizophrenia spectrum disorder (n = 203) and a randomly selected group of general population control users (n = 173) posted 1,544,122 tweets...
November 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28610482/randomised-controlled-trial-of-a-healthy-lifestyle-intervention-among-smokers-with-psychotic-disorders-outcomes-to-36-months
#14
Amanda L Baker, Robyn Richmond, Frances J Kay-Lambkin, Sacha L Filia, David Castle, Jill M Williams, Terry J Lewin, Vanessa Clark, Robin Callister, Kerrin Palazzi
OBJECTIVE: People living with psychotic disorders (schizophrenia spectrum and bipolar disorders) have high rates of cardiovascular disease risk behaviours, including smoking, physical inactivity and poor diet. We report cardiovascular disease risk, smoking cessation and other risk behaviour outcomes over 36 months following recruitment into a two-arm randomised controlled trial among smokers with psychotic disorders. METHODS: Participants ( N = 235) drawn from three sites were randomised to receive nicotine replacement therapy plus (1) a Healthy Lifestyles intervention delivered over approximately 9 months or (2) a largely telephone-delivered intervention (designed to control for nicotine replacement therapy provision, session frequency and other monitoring)...
March 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/28593623/-smoking-cessation-and-schizophrenia
#15
D P Muller, L de Haan
People with schizophrenia smoke about 5.6 times as much as people without the disease. This factor is a major but treatable cause of morbidity and mortality in this patient population. Nevertheless, health professionals make relatively little effort to discourage people from smoking or to give it up altogether.<br/> AIM: To increase health professionals' knowledge about possible therapeutic interventions that can help people with schizophrenia to stop smoking.<br/> METHOD: We studied the relevant literature...
2017: Tijdschrift Voor Psychiatrie
https://www.readbyqxmd.com/read/28584649/adherence-to-nice-guidance-on-lifestyle-advice-for-people-with-schizophrenia-a-survey
#16
Lizzie Swaby, Daniel Hind, Rebecca Gossage-Worrall, David Shiers, Jonathan Mitchell, Richard I G Holt
Aims and method The STEPWISE trial (STructured lifestyle Education for People WIth SchizophrEnia, schizoaffective disorder and first episode psychosis) is currently evaluating a lifestyle education programme in addition to usual care. However, it is difficult to define what constitutes 'usual care'. We aimed to define 'usual care' for lifestyle management in people with schizophrenia, schizoaffective disorder and first-episode psychosis in STEPWISE study sites. Ten National Health Service (NHS) mental health trusts participated in a bespoke survey based on the National Institute for Health and Care Excellence (NICE) guidance...
June 2017: BJPsych Bulletin
https://www.readbyqxmd.com/read/28550660/achieving-smoking-cessation-in-individuals-with-schizophrenia-special-considerations
#17
REVIEW
Corinne Cather, Gladys N Pachas, Kristina M Cieslak, A Eden Evins
Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is estimated to be from 64 to 79%. Smokers with schizophrenia have historically been excluded from most large nicotine-dependence treatment studies. However, converging evidence indicates that a majority of smokers with schizophrenia want to quit smoking, and that available pharmacotherapeutic smoking cessation aids are well tolerated by this population of smokers and are effective when combined with behavioral treatment...
June 2017: CNS Drugs
https://www.readbyqxmd.com/read/28414583/improved-depressive-symptoms-in-adults-with-schizophrenia-during-a-smoking-cessation-attempt-with-varenicline-and-behavioral-therapy
#18
Corinne Cather, Susanne Hoeppner, Gladys Pachas, Sarah Pratt, Eric Achtyes, Kristina M Cieslak, A Eden Evins
OBJECTIVE: Smoking prevalence rates are elevated in individuals with schizophrenia spectrum disorders (SSD) compared with the general population, with attendant disproportionate smoking-related morbidity and mortality. Pharmacotherapies that improve abstinence rates in this population are underutilized, partly due to concerns about neuropsychiatric safety, particularly for those with comorbid depression or prior suicide attempt. Prospective assessment of the psychiatric safety profile of varenicline in those with SSD is needed...
July 2017: Journal of Dual Diagnosis
https://www.readbyqxmd.com/read/28392208/minimal-effects-of-prolonged-smoking-abstinence-or-resumption-on-cognitive-performance-challenge-the-self-medication-hypothesis-in-schizophrenia
#19
Douglas L Boggs, Toral S Surti, Irina Esterlis, Brian Pittman, Kelly Cosgrove, R Andrew Sewell, Mohini Ranganathan, Deepak Cyril D'Souza
One prominent, long-standing view is that individuals with schizophrenia smoke cigarettes more than the general population to "self-medicate" cognitive deficits and other symptoms. This study tested the self-medication hypothesis by examining the effects of smoking abstinence and resumption on cognition in patients with schizophrenia. Nicotine-dependent smokers with schizophrenia (n=26) were trained on a cognitive battery and then hospitalized to achieve and maintain confirmed abstinence from smoking for ~1 week...
April 6, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28389889/nicotine-dependence-is-associated-with-depression-and-childhood-trauma-in-smokers-with-schizophrenia-results-from-the-face-sz-dataset
#20
Romain Rey, Thierry D'Amato, Laurent Boyer, Lore Brunel, Bruno Aouizerate, Fabrice Berna, Delphine Capdevielle, Isabelle Chereau, Gabrielle Chesnoy-Servanin, Hélène Denizot, Jean-Michel Dorey, Caroline Dubertret, Julien Dubreucq, Catherine Faget, Franck Gabayet, Christophe Lancon, Jasmina Mallet, David Misdrahi, Christine Passerieux, Aurélie Schandrin, Franck Schürhoff, Mathieu Urbach, Pierre Vidailhet, Pierre-Michel Llorca, Guillaume Fond
In a perspective of personalized care for smoking cessation, a better clinical characterization of smokers with schizophrenia (SZ) is needed. The objective of this study was to determine the clinical characteristics of SZ smokers with severe nicotine (NIC) dependence. 240 stabilized community-dwelling SZ smokers (mean age = 31.9 years, 80.4% male gender) were consecutively included in the network of the FondaMental Expert Centers for Schizophrenia and assessed with validated scales. Severe NIC dependence was defined by a Fagerstrom questionnaire score ≥ 7...
April 7, 2017: European Archives of Psychiatry and Clinical Neuroscience
keyword
keyword
74279
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"